ICR calls for change to bring immunotherapies to more cancer patients 22 Oct 2020 Major changes to the way immunotherapy drugs are researched and evaluated are essential if they are to become successful treatment options for many more types of cancers, leading cancer experts are warning. Find out more Show/Hide
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020 The ICR has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head and neck cancer. Find out more Show/Hide
ASCO 2020: New optimised precision radiotherapy can reduce swallowing difficulties for head and neck cancer patients 30 May 2020 A new optimised intensity-modulated radiation therapy (IMRT) could spare head and neck cancer patients’ adverse life-long side effects after treatment, new clinical trial results have shown. Find out more Show/Hide
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer 23 Nov 2019
ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer 04 Jun 2019
ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer 22 Oct 2018
Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund 13 Oct 2017